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chapter 6
Lyophilization has been used for more than 60 years to increase the storage stability 
of food, pharmaceuticals and enzymes. We chose cyclohexanone monooxygenase 
(CHMO) as a model enzyme to find suitable freeze-drying conditions for long-term 
storage of an isolated monooxygenase. CHMO is a NADPH-dependent FAD-containing 
Baeyer-Villiger monooxygenase (BVMO) known for its ability to catalyze a large number 
of oxidation reactions. Additives were tested, with a focus on establishing the optimal 
concentration of sugars and salts for enzyme stabilization during and after lyophiliza-
tion. The results were successfully transferred to a larger scale and to two other mono-
oxygenases, namely the BVMO cyclopentadecanone monooxygenase (CPDMO) and 
the heme-containing cytochrome P450 monooxygenase, P450 BM3. In the absence of 
a lyoprotectant, lyophilized P450 BM3 was almost completely inactivated while the 
lyophilized BVMOs quickly lost activity when stored at 50 °C. Lyophilization in the 
presence of 2% (w/v) sucrose gave the best results, with preservation of 80% of the 
activity of P450 BM3 upon lyophilization and almost complete protection against inac-
tivation of all tested monooxygenases when stored as lyophilizate at 50 °C.
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Introduction 
Monooxygenases catalyze the insertion of a single oxygen atom from O2 into an organic substrate. 
Because they often possess high regio- and stereoselectivity, monooxygenases can be employed for the 
biocatalytic production of high-value chemicals such as active pharmaceutical ingredients or meta-
bolic intermediates (Torres Pazmiño et al., 2010). Two monooxygenase classes are of special commer-
cial interest: cytochrome P450 monooxygenases (P450s) and Baeyer-Villiger monooxygenases (BVMOs).
BVMOs catalyze the conversion of ketones into esters, often with high regio- and enantioselectivity 
(Kadow et al., 2012; Leisch et al., 2011). BVMOs utilize a flavin cofactor to catalyze Baeyer-Villiger oxi da-
tions. The Baeyer-Villiger oxidation of 2-butanone to produce the polymer precursor methyl propanoate 
is an industrially relevant example (Eastham et al., 2013). Besides Baeyer-Villiger oxidations, these 
enzymes are also able to oxidize heteroatoms, such as the enantioselective oxidation of sulfides (Bong 
et al., 2013; Riva et al., 2007). Two BVMOs were chosen for this study. The first is the extensively studied 
cyclohexanone monooxygenase (CHMO) from Acinetobacter sp. NCIMB9871 (Chen et al., 1988; Ryerson 
et al., 1982), because it has been used as the prototypical BVMO for many years. Yet, CHMO is a rather 
labile enzyme (van Beek et al., 2014). The second is cyclopentadecanone monooxygenase (CPDMO) from 
Pseudomonas sp. strain HI-70 which was chosen because it is complements the biocatalytic potential 
of CHMO and can be expressed as recombinant protein (Beneventi et al., 2009; Fink et al., 2011; Iwaki 
et al., 2006).
P450s contain a heme cofactor as prosthetic group which is essential for catalysis. P450s are known for 
their role in human steroid metabolism and xenobiotic detoxification (Munro et al., 2013). Therefore they 
are a prime target for drug development in the pharmaceutical industry (Guengerich, 2002). P450s are 
also considered interesting biocatalysts, because the scope of catalyzed reactions is broad (Mansuy, 
1998) and numerous products of commercial interest are conceivable. Here we focus on P450 BM3 
(CYP102A1), derived from Bacillus megaterium, which in vivo catalyzes the hydroxylation of fatty acids 
(Boddupalli et al., 1990). P450 BM3 has become the model enzyme for many studies on P450 systems 
(Munro et al., 2002). 
Both storage stability and operational stability are highly relevant for biotechnological applica-
tions that depend on the use of the above-mentioned biocatalysts. For long-term storage of proteins, 
lyophilization is an attractive approach. In the case of P450s, the optimal conditions for lyophilization 
of several specific P450s have been investigated (Bauer et al., 1994; Blanquet et al., 2005; Chefson et al., 
2007; Zhao and Auclair, 2009). For BVMOs, most effort was put into protein engineering to increase the 
thermostability and thereby increase the operational stability (Opperman and Reetz, 2010; van Beek 
et al., 2012). In addition, several naturally stable BVMOs have been discovered (Beneventi et al., 2013; 
Fraaije et al., 2005). In the case of stable enzymes, lyophilization remains of interest because it simpli-
fies shipping and storage. Except for extending storage time, lyophilization allows the screening of 
new substrates without extensive knowledge of molecular biology and facilitates the use of enzymes in 
non-aqueous media (Serdakowski and Dordick, 2008). While lyophilization has been used in the past 
to prepare formulations of isolated BVMOs or of cell-free extract containing a BVMO, no optimization of 
the lyophilization conditions has been done.
Denaturation of an enzyme can occur by heating, freezing, agitation or by chemical degradation in an 
aqueous formulation. Lyophilization protects against these effects. Water-mediated processes such as 
Chapter 6 
Lyophilization conditions for the storage of monooxygenases
74
hydrolysis and deamidation are limited by the removal of water. Protein unfolding, aggregation and 
chemical modifications are diffusion controlled reactions. Drying an enzyme results in the formation 
of an amorphous phase. Below the glass transition temperature (Tg) of this amorphous state the rate of 
diffusion-controlled reactions is greatly reduced. However, additives might still be required because 
storage below the Tg is not always sufficient to keep the protein from degrading, especially at longer 
timescales. Additives might also be required to prevent aggregation during the lyophilization process 
or rehydration. Additives may also compensate for the loss of essential waters during lyophilization by 
forming hydrogen bonds with the protein (Allison et al., 1999). Sugars are widely used as lyoprotectants 
during freeze-drying, with sucrose, trehalose and mannitol being most commonly used (Souillac et al., 
2002; Wang et al., 2009). We focused on sucrose because it has the same protective effects as trehalose 
in many cases (Allison et al., 1999; Chefson et al., 2007), while being significantly cheaper. For different 
applications of the enzyme the use of sugars might not be preferred, and alternatives are required. 
Various compounds were tested that could also have beneficial effects: salts, reducing compounds, 
wetting agents, amino acids and phosphite, the substrate for the fused coenzyme regenerating enzyme. 
The initial optimization of sucrose concentrations and the testing of other additives were done with 
the prototype BVMO, CHMO. Conditions that were found to be stabilizing were transferred to CPDMO 
and P450 BM3 to test the general applicability of the additives for lyophilizing monooxygenases. The 
addition of sucrose was shown to be extremely beneficial for all three tested enzymes. Additionally, 
several stabilizing additives were discovered which might be useful in specific applications, specifi-
cally magnesium sulfate and serine.
Materials and methods
Chemicals, equipment and vectors
Chemicals were acquired from Sigma-Aldrich, Oriental Yeast Co., TCI Europe and Riedel-de Haën. An 
Alpha 2-4 LD plus freeze dryer (Christ) was used for lyophilization and a Synergy MX (BioTek) was 
used for all spectrophotometric work. An Äkta purifier (GE Healthcare) was used for purification. The 
gene coding for P450 BM3 was kindly provided by prof. B. Hauer (Stuttgart) on a pJoe vector and was 
subcloned into a pBAD vector using 5’-ttgggctaacaggaggaattacatatgacaattaaagaaatgcc-3’ as the forward 
and 5’aactcaatgatgatgatgatgatggtcgaccccagcccacacgtctttt-3’as the reverse primer.
Enzyme purification
PTDH-fused CHMO and CPDMO were expressed and purified as previously reported (Torres Pazmiño, 
et al. 2009), with the exception that no glycerol and DTT were added to the buffers. E. coli Top10 cells 
containing pBAD P450 BM3 were grown in 3 × 400 mL TBAmp in shaking flasks at 37 °C. Expression was 
induced by the addition of 0.02% L-arabinose at an OD600 of 0.7-0.8 and 0.5 mM δ-aminolevulinic 
acid was added. The cells were incubated for 48 h (17 °C at 180 rpm) after induction before they were 
harvested (2880 × g, 30 min) and washed once with ice cold sodium phosphate buffer (50 mM, pH 7.5). 
The cell pellet was stored at -20 °C. For purification all steps were carried out on ice to prevent inactiva-
tion of the enzyme. Cells were resuspended in 30 mL of the sodium phosphate buffer and lysed using 
sonication. The resulting crude extract was centrifuged (3645 × g, 40 min) and the supernatant was 
recovered. For ammonium sulfate precipitation the cell free extract was diluted to a protein concen-
tration of 20 mg/mL. P450 BM3 was precipitated at an ammonium sulfate concentration of 50% and 
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collected by centrifugation (17000 × g, 15 min) and resuspended in sodium phosphate buffer (50 mM, pH 
7.5). The enzyme was further purified by affinity chromatography using a 5 mL HF His trap column. The 
imidazole in the elution buffer was removed by a second step of ammonium sulfate precipitation with 
90% ammonium sulfate. The protein pellet was resuspended in Tris/HCl buffer (50 mM pH 7.5).
Lyophilization
50 µL aliquots containing 5-25 µM enzyme and different concentrations of additives in a 96-well PCR 
plate were covered with a semi-permeable AeraSeal (Sigma-Aldrich) cover and flash frozen in liquid 
nitrogen and subsequently freeze-dried overnight at 0.05-0.07 mbar without temperature control. To 
prevent the effect of the used buffer from having a large effect on the results, the concentration Tris/HCl 
buffer was reduced to 5 to 12 mM in the lyophilization samples.
Activity determination
The lyophilized cake was dissolved in a volume of buffer equal to the total volume before lyophilization. 
50 mM Tris/HCl pH 8.5 was used for the BVMOs or 50 mM Tris/HCl pH 7.5 for P450 BM3. When the hydro-
phobicity of the material was too high to allow fast dissolution, a short centrifugation step was used 
to completely submerge the cake. The enzyme was diluted to an appropriate concentration (0.05-0.3 
µM) in the presence of 0.5 mM cyclohexanone (for CHMO), 1.5 mM (±)-bicyclo[3.2.0]hept-2-en-6-one (for 
CPDMO) or 1.0 mM lauric acid (for P450 BM3). Reactions were started by the addition of NADPH to a final 
concentration of 150-500 µM, and initial rates at 25 °C were determined by following the absorbance 
at 340 nm. Reported data points are obtained from 3 to 6 samples that were taken from the same stock 
solution before lyophilization. Data is compared between conditions in the same batch, as the handling, 
freezing cycles and storage before lyophilization affect the rate of the enzyme in general.
Incubations
To simulate extended storage conditions, the lyophilized enzyme samples were incubated at 50 °C 
for 48 h (sucrose concentrations) or 72 h ( other additives) in a ventilated stove, covered by the same 
semi-permeably filter as used during lyophilization. For the time course measurement, samples were 
stored at room temperature and subsequently at 50 °C in an air ventilated stove for the required number 
of days.
Results and discussion
As freeze-drying is a technique that is generally very mild to the enzyme, extended storage times or 
elevated temperatures are required to see the small differences in stability caused by additives. In initial 
experiments, the thermostable enzyme phenylacetone monooxygenase (PAMO) was used (Fraaije, et 
al. 2005 ), but we were unable to accurately observe any degradation in short time periods (data not 
shown). This is in line with the observation that PAMO is thermostable and tolerates a variety of organic 
solvents. CHMO has been shown to be more labile and was used for further experiments (van Beek, et al. 
2012 ). CHMO lost more than half of its activity upon lyophilization without any additives, and lost most 
of its residual activity within days when stored at 50 °C (Fig. 1). These initial results showed that addi-
tives could play an important role in creating a stabilized formulation of a labile enzyme like CHMO. 
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Figure 1: Percentage of residual activity of CHMO after lyophilization without additives and incubation at 50 °C. 
The activity of the enzyme before lyophilization is set to 100%. Standard errors shown are from 3 measurements.
To determine the stabilizing effect of different concentrations of additives, we chose to store the enzyme 
for a short time at elevated temperatures to amplify differences caused by these additives. Lyophilized 
samples were incubated at 50 °C before measuring the activity of the enzyme. As a starting point the 
inexpensive disaccharide sucrose was used as a lyoprotectant. Several concentrations of sucrose were 
tested to find the optimal concentration. Around 10 to 50 mg/mL sucrose in the enzyme solution was 
found to optimally preserve activity (Fig. 2). Theses concentrations were used in combination with 
2.5 mg/mL enzyme. This indicates that the protein is embedded in a sugar-matrix, and the protecting 
effect is probably not only caused by a few key sucrose molecules bound to the enzyme to replace water, 
but also because of an amorphous bulk-phase formed by sugar. While low sucrose concentrations were 
not effective in stabilization, also relatively high doses of sucrose (>50 mg/mL) decreased the stability of 
the monooxygenase upon lyophilization.
Figure 2: Observed rates of CHMO after lyophilization, incubation at 50 °C for 72 h and reconstitution of the enzyme. 
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Previously two P450s were stabilized by a much higher concentrations of sucrose. But also in those 
cases lower activities at relatively high concentrations of sucrose are observed (Chefson et al., 2007). 
No explanation was given for the reduction of activity by added sucrose. A possible explanation is that 
amorphous sucrose has a Tg that is lower than that of the protein. At higher sucrose concentrations the 
Tg might be lowered below the 50 °C storage temperature, leading to inactivation. The increased stability 
caused by the addition of only a small amount of sucrose might result from the formation of hydrogen 
bonds with the protein in the place of the removed water (Allison et al., 1999).
A sugar that is often used to stabilize proteins is trehalose. No additional stabilization could be observed 
as compared to sucrose by the addition of 10 mg/mL trehalose (Fig. S1). The often superior stabilizing 
effect of trehalose is attributed to its higher hydration radius, allowing the retention of more water in 
the dried protein state. This effect could also be achieved by using larger quantities of sucrose. No other 
sugars were tested because the sucrose-lyophilized enzyme already performed as good as enzyme 
frozen in liquid N2 and stored at -80 °C (Fig. S1). Improving the stability more would be improbable.
To facilitate the use of enzymes in biocatalytic applications, other classes of compounds were tested 
which might interfere less with specific assays or product purifications. Some compounds were also 
tested because they could be already present in the protein preparation or are required for downstream 
applications. An obvious candidate is ammonium sulfate because this salt is extensively used to 
precipitate proteins. Other ammonium and sulfate salts were also tested (Fig. 3 and Fig. S2 and S3) to find 
out whether the ion or the cation would be responsible for the stabilization. Ammonium sulfate itself did 
not stabilize the enzyme upon lyophilization. We also observed that ammonium sulfate is interfering 
with the stabilizing effect of sucrose. The combined sucrose and ammonium sulfate formulation 
performed worse than the formulation containing only sucrose (Fig. 3). However, a stabilizing effect of 
magnesium sulfate was discovered. 25 mM MgSO4 protected the lyophilized enzyme as well as 20 mg/
mL sucrose. Magnesium chloride completely destabilizes the enzyme when used as the only additive. 
However, it does have a beneficial effect when adding it in combination with sucrose. This might be 
caused by the ability of the salt to form salt bridges with the enzyme which are not formed when only 
sucrose is present.
Figure 3: Observed rates of CHMO containing various additives after lyophilization and 48 h incubation at 50 °C. 
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When sucrose and stabilizing salts were present, phosphite could be added to the enzyme mix without 
significantly affecting the activity. In the case of sucrose and ammonium sulfate the activity is even 
increased by the addition of phosphite (Fig. 3). Phosphite was tested because of its use as sacrificial 
substrate for NADPH regeneration (Torres Pazmiño et al., 2009). The addition of phosphite could be 
useful for small lab-scale conversions. In the current formulation 50 mM was used, resulting in a highest 
possible value for the total turnover number of only 2000 (the concentration of phosphite is only 2000 
fold the concentration of enzyme). This makes it not suitable for any large-scale process because this 
leads to excessive enzyme loading (Rogers and Bommarius, 2010). The addition of both phosphite and 
NADP+ in the formulation would make the enzyme ready to use for smaller scale conversions. 
Tween 20 was tested for its potential to help with the re-solubilization step by acting as a wetting agent. 
The wetting of the protein foam formed upon lyophilization was problematic in some formulations 
because it appeared to be very hydrophobic. Serine and cysteine were also used to see if amino acids 
could take over the role of sugars, salts or wetting agents. Tween 20 was not very effective by itself, but 
serine stabilized CHMO. The similar amino acid cysteine was not found to stabilize the enzyme, even if 
it could have protective effect by acting as a reducing agent. 
Figure 4: Observed rates of CHMO (A), CPDMO (B) and P450 BM3 (C) after incubation for 72 h as lyophilized samples 
at different conditions. Lyophilized samples were stored at room temperature or at 50 °C. Activities in the absence of 
sucrose as lyoprotectant in light gray, activities in the presence of 20 mg/mL sucrose in dark gray. Standard errors 
are determined from three lyophilization samples. 
The optimal concentration of sucrose (20 mg/mL) was also used in the lyophilization of two other 
monooxygenases, to see if the stabilizing effect was specific for CHMO or applicable to a wider range 
of enzymes. The sequence-related and relatively labile CPDMO, and the widely used P450 BM3 were 
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CHMO is cleary more stable when stored at -80 °C compared to 4 °C. Lyophilization also results in the 
loss of significant activity. The reverse is the case for CPDMO; this enzyme loses activity when frozen 
while storage at 4 °C preserves most activity. This agrees with previous results (unpublished) that indi-
cate that CPDMO should not be frozen. P450 BMO3 is relatively unaffected by freezing and lyophilization 
in the presence of sucrose. In constrast to the other monooxygenases, the activity after lyophilization in 
the absence of sucrose results in the loss of most activity. Gratifyingly, it was found that, as for CHMO, 
sucrose stabilized both enzymes upon lyophilization.
Conclusions
Conditions that improved the stability of lyophilized BVMO CHMO were determined and transferred 
to the homologous CPDMO and P450 BM3. The use of 6.5-45 mg/mL sucrose was highly effective in 
obtaining a stable lyophilized monooxygenase samples. Also alternative additives were identified. For 
example, serine was also found to stabilize CHMO upon lyophilization. We have also shown a (co )
substrate can be used as an additive during lyophilization. These findings might facilitate the easier 
distribution of more stable and applicable lyophilized formulations of both BVMOs and P450s. These 
findings will be helpful for future biocatalytic applications that involve monooxygenases. 
Acknowledgements
HL van Beek was supported by the EU 7th framework programme Oxygreen and N Beyer was supported 
by the P4FIFTY FP7 funded European Marie Curie Training network. 
Chapter 6 
Lyophilization conditions for the storage of monooxygenases
80
Allison SD, Chang B, Randolph TW, Carpenter JF. 1999. 
Hydrogen Bonding between Sugar and Protein Is Responsible 
for Inhibition of Dehydration-Induced Protein Unfolding. Arch. 
Biochem. Biophys. 365:289-298. 
Bauer C, Corsi C, Paolini M. 1994. Stability of microsomal mono-
oxygenases in murine liver S9 fractions derived from pheno-
barbital and ϐ-naphthoflavone induced animals under various 
long-term conditions of storage. Teratog. Carcinog. Mutagen. 
14:13-22. 
Beneventi E, Niero M, Motterle R, Fraaije M, Bergantino E. 2013. 
Discovery of Baeyer-Villiger monooxygenases from photosyn-
thetic eukaryotes. J. Mol. Catal. B. 98:145-154. 
Beneventi E, Ottolina G, Carrea G, Panzeri W, Fronza G, Lau 
PCK. 2009. Enzymatic Baeyer–Villiger oxidation of steroids 
with cyclopentadecanone monooxygenase. J. Mol. Catal. B. 
58:164-168. 
Blanquet S, Garrait G, Beyssac E, Perrier C, Denis S, Hébrard 
G, Alric M. 2005. Effects of cryoprotectants on the viability and 
activity of freeze dried recombinant yeasts as novel oral drug 
delivery systems assessed by an artificial digestive system. Eur. 
J. Pharm. Biopharm. 61:32-39. 
Boddupalli SS, Estabrook RW, Peterson JA. 1990. Fatty acid 
monooxygenation by cytochrome P-450BM-3. J.  Biol. Chem. 
265:4233-4239. 
Bong YK, Clay MD, Collier SJ, Mijts B, Vogel M, Zhang X, Zhu J, 
Nazor J, Smith D, Song S. 2013. Synthesis of prazole compounds. 
EP2010836590. 
Chefson A, Zhao J, Auclair K. 2007. Sugar-mediated lyoprotec-
tion of purified human CYP3A4 and CYP2D6. J. Biotechnol. 
130:436-440. 
Chen Y, Peoples O, Walsh C. 1988. Acinetobacter cyclohexanone 
monooxygenase: gene cloning and sequence determination. J. 
Bacteriol. 170:781-789. 
Fink MJ, Fischer TC, Rudroff F, Dudek H, Fraaije MW, Mihovi-
lovic MD. 2011. Extensive substrate profiling of cyclopentade-
canone monooxygenase as Baeyer-Villiger biocatalyst reveals 
novel regiodivergent oxidations. J. Mol. Catal. B. 73:9-16
Fraaije MW, Wu J, Heuts DP, van Hellemond EW, Spelberg JH, 
Janssen DB. 2005. Discovery of a thermostable Baeyer-Vil-
liger monooxygenase by genome mining. Appl. Microbiol. 
Biotechnol. 66:393-400. 
Guengerich FP. 2002. Cytochrome P450 enzymes in the genera-
tion of commercial products. Nat. Rev. Drug Discov. 1:359-366. 
Huijbers MME, Montersino S, Westphal AH, Tischler D, van 
Berkel WJH. 2014. Flavin dependent monooxygenases. Arch. 
Biochem. Biophys. 544:2-17. 
Iwaki H, Wang S, Grosse S, Bergeron H, Nagahashi A, Lertvo-
rachon J, Yang J, Konishi Y, Hasegawa Y, Lau PCK. 2006. Pseu-
domonad Cyclopentadecanone Monooxygenase Displaying an 
Uncommon Spectrum of Baeyer-Villiger Oxidations of Cyclic 
Ketones. Appl. Environ.Microbiol. 72:2707-2720. 
Kadow M, Loschinski K, Mallin H, Saß S, Bornscheuer U. 2012. 
Discovery, application and protein engineering of Baeyer-Vil-
liger monooxygenases for organic synthesis. Org. Biomol. 
Chem. 10:6249-6265. 
Leisch H, Morley K, Lau PCK. 2011. Baeyer-Villiger monooxy-
genases: More than just green chemistry. Chem. Rev. 111:4165-
4222. 
Mansuy D. 1998. The great diversity of reactions catalyzed by 
cytochromes P450. Comp. Biochem. Phys. C.121:5-14. 
Munro AW, Girvan HM, Mason AE, Dunford AJ, McLean KJ. 
2013. What makes a P450 tick? Trends Biochem. Sci. 38:140-150. 
Munro AW, Leys DG, McLean KJ, Marshall KR, Ost TWB, Daff S, 
Miles CS, Chapman SK, Lysek DA, Moser CC, Page CC, Dutton 
PL. 2002. P450 BM3: the very model of a modern flavocyto-
chrome. Trends Biochem. Sci. 27:250-257. 
Opperman DJ, Reetz MT. 2010. Towards practical Baeyer-Vil-
liger monooxygenases: Design of cyclohexanone monooxy-
genase mutants with enhanced oxidative stability. ChemBio-
Chem 11:2589-2596. 
Riva S, Fassi P, Allegrini P, Razzetti G. 2007. Process for the 
preparation of (−) modafinil. EP1777295A2 
Rogers TA, Bommarius AS. 2010. Utilizing simple biochem-
ical measurements to predict lifetime output of biocatalysts in 
continuous isothermal processes. Chem. Eng. Sci. 65:2118-2124. 
Ryerson CC, Ballou DP, Walsh C. 1982. Mechanistic studies on 
cyclohexanone oxygenase. Biochemistry. 21:2644-2655. 
Serdakowski AL, Dordick JS. 2008. Enzyme activation for 
organic solvents made easy. Trends Biotechnol. 26:48-54. 
References
Chapter 6 
Lyophilization conditions for the storage of monooxygenases
81
Souillac PO, Costantino HR, Middaugh CR, Rytting JH. 2002. 
Investigation of protein/carbohydrate interactions in the dried 
state. 1. Calorimetric studies. J. Pharm. Sci. 91:206-216. 
Torres Pazmiño DE, Riebel A, de Lange J, Rudroff F, Mihovilovic 
MD, Fraaije MW. 2009. Efficient biooxidations catalyzed by a 
new generation of self-sufficient Baeyer–Villiger monooxygen-
ases. ChemBioChem. 10:2595-2598. 
Torres Pazmiño D, Winkler M, Glieder A, Fraaije M. 2010. Mono-
oxygenases as biocatalysts: Classification, mechanistic aspects 
and biotechnological applications. J. Biotechnol. 146:9-24. 
van Beek HL, de Gonzalo G, Fraaije MW. 2012. Blending Baey-
er-Villiger monooxygenases: Using a robust BVMO as a scaffold 
for creating chimeric enzymes with novel catalytic properties. 
Chem. Commun. 48:3288-3290. 
van Beek HL, Wijma HJ, Fromont L, Janssen DB, Fraaije MW. 
2014. Stabilization of cyclohexanone monooxygenase by a 
computationally designed disulfide bond spanning only one 
residue. FEBS Open Bio. 4:168-174
Wang B, Tchessalov S, Warne NW, Pikal MJ. 2009. Impact of 
sucrose level on storage stability of proteins in freeze-dried 
solids: I. correlation of protein-sugar interaction with native 
structure preservation. J. Pharm. Sci. 98:3131-3144. 
Zhao J, Auclair K. 2009. The activity of human CYP2D6 in low 
water organic solvents. Biotechnol. Bioeng. 102:1268-1272. 
Chapter 6 
Lyophilization conditions for the storage of monooxygenases
82
Chapter 6 
Lyophilization conditions for the storage of monooxygenases
83
